Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain by Eduardo Anguita, Francisco Javier Parrondo García, José Ramón González-Porras

Subjects: Get full text

Cost-minimization and budget impact analysis of bypassing agents in hemophilia A with inhibitors: a Brazilian study by Christiane Maria da Silva Pinto, André Luis Souza Silveira, Fábio Carvalho, Janaina da Silva, Tatiane Bomfim Ribeiro, Gabriela Vilela de Brito

Subjects: Get full text